Najib Nassani1, Georges Khayat, Issam Raad, Ying Jiang, Nada Alaaeddine, George Hilal. 1. Cancer and Metabolism Research Laboratory, Saint-Joseph University, Faculty of Medicine, Beirut, Lebanon; Pulmonary and Critical Care Division, Hotel-Dieu de France Hospital, Saint-Joseph University, Faculty of Medicine, Beirut, Lebanon.
Abstract
OBJECTIVES: The diagnosis of lung cancer remains difficult especially in peripheral tumors, given the absence of relevant markers and of sensitive imaging techniques. Telomerase is a ribonucleotide enzyme responsible for the immortalization of cancerous cells and seems to increase in bronchial aspirates of lung cancer patients. The purpose of our study is to further investigate the value of telomerase measurement in bronchial aspirates as a diagnostic tool for lung cancer. DESIGN AND METHODS: Random 82 bronchial aspirates were obtained from patients undergoing bronchoscopy to diagnose any lung illness including inflammation and cancer. Cytology examination, quantification of proteins by Bradford method, and telomerase activity measurement by quantitative Real-time PCR were performed. Out of 82 specimens, 11 were excluded because of hemolysis, absence of elements or lack of final diagnosis. ROC curve analysis was done. RESULTS: A significant difference in telomerase activity average was noted between normal patients and those with inflammation and cancer. Discriminatory capacity of telomerase activity was: for cancer vs. non cancer, AUC =0.74 (95% CI: 0.62-0.84), sensitivity=78%, specificity=72%, Negative Predictive Value=87%, at cut-off >0.46 atmol/mg protein/20 min; for cancer vs. normal, AUC=0.87 (95% CI: 0.72-0.96), se=78%, sp=92%, NPV=71%, at cut-off >0.46; for cancer vs. inflammation, AUC=0.69 (95% CI: 0.55-0.80), se=74%, sp=70%, NPV=79%, at cut-off >1.03, and for inflammation vs. normal, AUC=0.76 (95% CI: 0.62-0.88), se=79%, sp=77%, NPV=59%, at cut-off >0. CONCLUSION: Telomerase activity in bronchial aspirates is a promising diagnostic marker for lung cancer and inflammation detection.
OBJECTIVES: The diagnosis of lung cancer remains difficult especially in peripheral tumors, given the absence of relevant markers and of sensitive imaging techniques. Telomerase is a ribonucleotide enzyme responsible for the immortalization of cancerous cells and seems to increase in bronchial aspirates of lung cancerpatients. The purpose of our study is to further investigate the value of telomerase measurement in bronchial aspirates as a diagnostic tool for lung cancer. DESIGN AND METHODS: Random 82 bronchial aspirates were obtained from patients undergoing bronchoscopy to diagnose any lung illness including inflammation and cancer. Cytology examination, quantification of proteins by Bradford method, and telomerase activity measurement by quantitative Real-time PCR were performed. Out of 82 specimens, 11 were excluded because of hemolysis, absence of elements or lack of final diagnosis. ROC curve analysis was done. RESULTS: A significant difference in telomerase activity average was noted between normal patients and those with inflammation and cancer. Discriminatory capacity of telomerase activity was: for cancer vs. non cancer, AUC =0.74 (95% CI: 0.62-0.84), sensitivity=78%, specificity=72%, Negative Predictive Value=87%, at cut-off >0.46 atmol/mg protein/20 min; for cancer vs. normal, AUC=0.87 (95% CI: 0.72-0.96), se=78%, sp=92%, NPV=71%, at cut-off >0.46; for cancer vs. inflammation, AUC=0.69 (95% CI: 0.55-0.80), se=74%, sp=70%, NPV=79%, at cut-off >1.03, and for inflammation vs. normal, AUC=0.76 (95% CI: 0.62-0.88), se=79%, sp=77%, NPV=59%, at cut-off >0. CONCLUSION: Telomerase activity in bronchial aspirates is a promising diagnostic marker for lung cancer and inflammation detection.
Authors: George Hilal; Ruth Reitzel; Zainab Al Hamal; Anne-Marie Chaftari; Iba Al Wohoush; Ying Jiang; Ray Hachem; Issam I Raad Journal: PLoS One Date: 2017-05-03 Impact factor: 3.240
Authors: Lynnette R Ferguson; Helen Chen; Andrew R Collins; Marisa Connell; Giovanna Damia; Santanu Dasgupta; Meenakshi Malhotra; Alan K Meeker; Amedeo Amedei; Amr Amin; S Salman Ashraf; Katia Aquilano; Asfar S Azmi; Dipita Bhakta; Alan Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Hiromasa Fujii; Gunjan Guha; Dorota Halicka; William G Helferich; W Nicol Keith; Sulma I Mohammed; Elena Niccolai; Xujuan Yang; Kanya Honoki; Virginia R Parslow; Satya Prakash; Sarallah Rezazadeh; Rodney E Shackelford; David Sidransky; Phuoc T Tran; Eddy S Yang; Christopher A Maxwell Journal: Semin Cancer Biol Date: 2015-04-11 Impact factor: 17.012